The experience of using fesoterodine in patients with overactive bladder in the older age group
Aim. To evaluate the effectiveness and tolerability of the drug fezoterodin in older patients with оveractive bladder (OAB). Materials and methods. In 2019, 50 women with OAB aged 50 to 82 years (average age was 67.512.5 years) were treated in the framework of donation of the drug fezoterodin (To...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Berlin A.V.
2020-05-01
|
| Series: | Гинекология |
| Subjects: | |
| Online Access: | https://gynecology.orscience.ru/2079-5831/article/viewFile/33969/21627 |
| _version_ | 1828739998153703424 |
|---|---|
| author | Elena I. Ermakova |
| author_facet | Elena I. Ermakova |
| author_sort | Elena I. Ermakova |
| collection | DOAJ |
| description | Aim. To evaluate the effectiveness and tolerability of the drug fezoterodin in older patients with оveractive bladder (OAB).
Materials and methods. In 2019, 50 women with OAB aged 50 to 82 years (average age was 67.512.5 years) were treated in the framework of donation of the drug fezoterodin (Toviaz). The patients were divided into two groups: group 1 included 25 women had received treatment with fesoterodine dose of 4 mg per day for 12 weeks, group 2 consisted of 25 women, the fesoterodine dose to 8 mg per day for 12 weeks. The diagnosis of OAB was confirmed by a urodynamic study.
Results. 48 (96%) patients out of 50 completed a 12 week course of treatment. The efficacy and tolerability of the drug fezoterodin in both groups was 93.7%. Mild adverse events (dry mouth, constipation, blurred vision) were observed in 11 (22.9%) patients out of 48 treated. None of the women had cognitive impairment (memory impairment, decreased concentration, drowsiness, impaired thinking and orientation).
Conclusion. Our experience with M-cholinoblocator fezoterodin showed statistically and clinically significant improvements in all symptoms of OAB, as well as good tolerability of the drug in patients aged 50 to 82 years. |
| first_indexed | 2024-04-13T00:32:28Z |
| format | Article |
| id | doaj.art-8e59721d796047b08b7b829bd1dfe381 |
| institution | Directory Open Access Journal |
| issn | 2079-5696 2079-5831 |
| language | Russian |
| last_indexed | 2024-04-13T00:32:28Z |
| publishDate | 2020-05-01 |
| publisher | IP Berlin A.V. |
| record_format | Article |
| series | Гинекология |
| spelling | doaj.art-8e59721d796047b08b7b829bd1dfe3812022-12-22T03:10:26ZrusIP Berlin A.V.Гинекология2079-56962079-58312020-05-01221454910.26442/20795696.2020.1.20006730641The experience of using fesoterodine in patients with overactive bladder in the older age groupElena I. Ermakova0Kulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologyAim. To evaluate the effectiveness and tolerability of the drug fezoterodin in older patients with оveractive bladder (OAB). Materials and methods. In 2019, 50 women with OAB aged 50 to 82 years (average age was 67.512.5 years) were treated in the framework of donation of the drug fezoterodin (Toviaz). The patients were divided into two groups: group 1 included 25 women had received treatment with fesoterodine dose of 4 mg per day for 12 weeks, group 2 consisted of 25 women, the fesoterodine dose to 8 mg per day for 12 weeks. The diagnosis of OAB was confirmed by a urodynamic study. Results. 48 (96%) patients out of 50 completed a 12 week course of treatment. The efficacy and tolerability of the drug fezoterodin in both groups was 93.7%. Mild adverse events (dry mouth, constipation, blurred vision) were observed in 11 (22.9%) patients out of 48 treated. None of the women had cognitive impairment (memory impairment, decreased concentration, drowsiness, impaired thinking and orientation). Conclusion. Our experience with M-cholinoblocator fezoterodin showed statistically and clinically significant improvements in all symptoms of OAB, as well as good tolerability of the drug in patients aged 50 to 82 years.https://gynecology.orscience.ru/2079-5831/article/viewFile/33969/21627оveractive bladderurgencyurinary disordersnocturiaurinary incontinenceantimuscarinic drugs |
| spellingShingle | Elena I. Ermakova The experience of using fesoterodine in patients with overactive bladder in the older age group Гинекология оveractive bladder urgency urinary disorders nocturia urinary incontinence antimuscarinic drugs |
| title | The experience of using fesoterodine in patients with overactive bladder in the older age group |
| title_full | The experience of using fesoterodine in patients with overactive bladder in the older age group |
| title_fullStr | The experience of using fesoterodine in patients with overactive bladder in the older age group |
| title_full_unstemmed | The experience of using fesoterodine in patients with overactive bladder in the older age group |
| title_short | The experience of using fesoterodine in patients with overactive bladder in the older age group |
| title_sort | experience of using fesoterodine in patients with overactive bladder in the older age group |
| topic | оveractive bladder urgency urinary disorders nocturia urinary incontinence antimuscarinic drugs |
| url | https://gynecology.orscience.ru/2079-5831/article/viewFile/33969/21627 |
| work_keys_str_mv | AT elenaiermakova theexperienceofusingfesoterodineinpatientswithoveractivebladderintheolderagegroup AT elenaiermakova experienceofusingfesoterodineinpatientswithoveractivebladderintheolderagegroup |